-
Cotation en bourse
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLire la suiteSeamless listing, trading, clearing and settlement for fixed income
-
Trading
Where European Government Bonds meet the futureFixed Income derivativesLire la suite
Trade Mini Bond Futures on main European Government Bonds
-
Clearing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLire la suite
Seamless listing, trading, clearing and settlement for fixed income
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLire la suiteEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lire la suiteThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Données de marché
-
Indices
Access the white paperNext generation of indicesLire la suiteThis white paper marks the second edition of Euronext’s Index Outlook series, a recurring publication designed to give investors deeper insight into our index innovation agenda and the structural forces shaping global markets.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lire la suiteShaping capital markets for future generations
Abivax
26/06/2015
Enternext accueille Abivax sur Euronext à Paris
Professeur Hartmut Ehrlich, Directeur Général d'Abivax, sonne la clôture des marchés boursiers.
Abivax est spécialisé dans la recherche, le développement et la commercialisation de médicaments antiviraux et de vaccins thérapeutiques destinés au traitement des maladies infectieuses sévères.
A fin 2014, le groupe dispose d'un portefeuille de 3 produits en phase de développement clinique : ABX203 (vaccin thérapeutique contre l'hépatite B chronique), ABX464 (nouvelle molécule contre le VIH) et ABX196 (adjuvant vaccin contre l'hépatite B).